GlassScriptPhysician profile
Ira Vohra
NPI 1871769125
$12,438.82
in general payments reported to CMS, 2019-2025
39 companies · $3,037 in 2025
The $3,037 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $455 · 2021: $912 · 2022: $2,306 · 2023: $2,478 · 2024: $2,768 · 2025: $3,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,283.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,917.71 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,727.98 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,344.48 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $888.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $747.46 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $633.15 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.46 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $480.52 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $361.79 | 2019-2025 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $347.43 | 2023-2025 | Rexulti |
| Shield Therapeutics INC | $315.05 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.38 | 2021-2025 | Xifaxan |
| Abbott Laboratories | $269.60 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $229.12 | 2022-2023 | Injectafer |
| Radius Health, INC. | $215.94 | 2023-2025 | Tymlos |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $200.50 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $184.59 | 2022 | |
| Sunovion Pharmaceuticals INC. | $168.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $163.15 | 2019-2023 | Spravato |
| Phathom Pharmaceuticals, INC. | $157.20 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $151.64 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $112.25 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $107.68 | 2020-2025 | Veozah |
| Verona Pharma, INC. | $106.74 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $105.34 | 2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $98.81 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $86.01 | 2022-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Paratek Pharmaceuticals, INC. | $79.61 | 2022-2023 | Nuzyra |
| Axsome Therapeutics, INC. | $78.08 | 2024-2025 | Auvelity |
| Dexcom, INC. | $74.95 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $59.27 | 2021 | |
| Amarin Pharma, INC. | $43.33 | 2019 | |
| Eisai INC. | $41.57 | 2022 | |
| Biogen, INC. | $19.73 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.38 | 2021 | |
| Janssen Biotech, INC. | $15.91 | 2019 | |
| Ibsa Pharma INC. | $15.56 | 2020 | |
| Almatica Pharma LLC | $13.27 | 2022 | |
| Esperion Therapeutics, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Vohra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.